Navigation Links
Breast cancer heterogeneity no barrier to predictive testing, study shows
Date:5/2/2013

n profiling on their 78 samples using oligonucleotide microarrays. Overall, they found that the gene expression profiles of the cores were variable, and in at least 5 patients this heterogeneity was substantial.

However, when they analysed a number of multi-gene signatures selected from previous studies, this heterogeneity was considerably less significant.

The gene sets differed in their variance between biopsies, the authors found. The most pronounced heterogeneity was observed in immune response-related genes, while the least heterogeneous were the classifiers based on genes selected by advanced bioinformatical methods from both cell culture experiments and patient tissues.

"Overall, the heterogeneity among the potentially predictive genes was small enough and we conclude that this factor should not prohibit their effective use in clinical practice," Dr Jarząb says.

"Our study confirms that it is possible to address tumour heterogeneity when carrying out routine diagnostic procedures in patients. Our results may help to introduce the better tailoring of preoperative treatment."

Commenting on the results, Dr. Angelo Di Leo, Head of the Sandro Pitigliani Medical Oncology Unit and Chair of the Oncology Department at the Hospital of Prato, Istituto Toscano Tumori, Italy, said: "If other studies report similar results to this one, then it could become common practice to evaluate prognostic or predictive breast cancer markers from more than one primary tumour area."

"The study is innovative because it is one of the first to address the question of intratumour heterogeneity. It means that not all the cells from the same tumour have the same characteristics, and if we want to have a clear picture of the tumour biology we should not limit the evaluation of tumour markers to one area of the tumour itself," Dr. Di Leo said.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Big data analysis identifies prognostic RNA markers in a common form of breast cancer
2. Cold winters freezing out breast cancer treatment
3. Identified as responsible for breast and ovarian hereditary cancer 3 mutations at BRCA1 gene
4. An important discovery in breast cancer by IRCM researchers
5. UCLA researchers find nanodiamonds could improve effectiveness of breast cancer treatment
6. IMPAKT -- Translational research breast cancer conference
7. LSUHSC research discovers new drug target for metastatic breast cancer
8. AACR news: Studies show increasing evidence that androgen drives breast cancer
9. AACR news: Six2 homeoprotein allows breast cancer cells to detach and metastasize
10. AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
11. Certain breast cancers have a trait that could be attacked by new therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... method to make payments.  With this patent, NXT-ID ... its groundbreaking voice-direct payment patent application, with behavior-directed ...
(Date:7/8/2015)... -- Summary Pancreatic cancer is the 12th most ... a mortality rate of 10.9 deaths per 100,000 people ... has highlighted a significant need for new and improved ... the current market. A highly active pancreatic cancer ... types and mechanisms of action, which provides a striking ...
(Date:7/7/2015)... July 7, 2015  Based on its recent ... Sullivan recognizes Credence ID, LLC with the 2015 ... of the Year Award. Credence ID has developed ... its mission of offering enrollment and identification solutions ... Credence ID was formed by experts from the ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... major study sheds new light on the role of carbon ... indicates that instead of sinking, carbon dioxide is often consumed ... a dimly lit area 100 to 1,000 meters below the ... where it can be stored and prevented from re-entering the ...
... from preterm birth are staggering. In Canada, outlays for ... be almost $2 billion per year. In a 5-year, ... to mothers who had entered premature labor led to ... the study are reported in the January issue of ...
... New predictions about bird flu, involving the use of ... antiviral drugs might be the best way to deal ... has not triggered a worldwide human epidemic yet because ... this ability, it would take 6-8 months to develop ...
Cached Biology News:Ocean's 'twilight zone' may be a key to understanding climate change 2
(Date:7/29/2015)... 29, 2015 Research ... addition of the "Global Biosimilars Market, 2015 ... The Global Biosimilars Market, 2015 - 2025, ... growing biosimilars market. With the blockbuster biologics losing ... costs, biosimilars are being viewed as viable substitutes ...
(Date:7/29/2015)... 2015  Therapath Neuropathology ( www.Therapath.com ), a ... VA and Military Medical centers both domestically and ... and Sweat Gland Nerve Fiber Density (SGNFD) for ... ). Demonstration of a reduction ... punch skin biopsy is a highly sensitive and ...
(Date:7/29/2015)... ... 2015 , ... The third Medical Innovation Impact Index (MI3) Alert considers FDA ... combinations. The current system received a score of 0 (range -10 to +10) for ... of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. ...
(Date:7/29/2015)... , ... July 29, 2015 , ... Finding gooey or ... is quite normal. Although there are a considerable number of terms in popular use ... this post-sleep material is a mixture of mucus, blood cells, skin cells and dust, ...
Breaking Biology Technology:Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Neuropathology services for VA and Military health systems 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4
... CAMBRIDGE, Mass. - MIT researchers have created a new detector ... an explosive such as TNT. To create the sensors, ... hollow, one-atom-thick cylinders made of pure carbon with protein ... time those proteins have been shown to react to explosives, ...
... PDL BioPharma, Inc. (PDL, the Company) (NASDAQ: ... to market and other conditions, $135 million aggregate principal amount ... Company,s shelf registration statement filed with the U.S. Securities and ... expects to grant the underwriters a 13-day overallotment option to ...
... 2011 The U.S. Food and Drug Administration is requesting ... development of a user fee program for biosimilar and ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Biological products are produced ... or animal cell, while small molecule drugs are typically ...
Cached Biology Technology:MIT news: New sensor can detect tiny traces of explosives 2MIT news: New sensor can detect tiny traces of explosives 3PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 2PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 3PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 4PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 5FDA Requests Input on Development of User Fee Program for Biosimilar and Interchangeable Biological Products 2
6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE)...
...
X-Gal, 100 mg. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzy...
...
Biology Products: